US equities |
MU $1,068.28 ▼-1.81% NVDA $236.15 ▼-0.56% PLTR $201.68 ▲+3.89% SNDK $1,647.29 ▼-2.67% META $721.38 ▲+0.01% AMD $637.38 ▼-1.31% INTC $110.06 ▼-2.71% TSLA $372.09 ▼-1.51%
FinancialContent

Articles published by VeriSIM Life

News headline image
Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Awarded U.S. Government Agreement to Advance New Approach Methodologies for Drug Development
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life CEO Dr. Jo Varshney Shares Pioneering Approach to Business and Life with MSNBC Mika Brzezinski's Know Your Value Platform
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders
From VeriSIM Life
Via Business Wire
Tickers ASX:TTB
News headline image
VeriSIM Life Announces Acquisition of Molomics Biotech
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Awarded Federal Grant from National Institutes of Health for Substance Use Disorder Drug Discovery and Development
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life to Present at Biotech Showcase and Participate in BIO Partnering at JPM Week
From VeriSIM Life
Via Business Wire
News headline image
VeriSIM Life Secures $15 Million Series A Funding
From VeriSIM Life
Via Business Wire